Telehealth Lobby Down To Wire Without CBO Scores, Unofficial Estimates At Low Single-Figure Billions

Lobbyists still don’t have official Congressional Budget Office scores as they are down to the wire to get lawmakers to extend telehealth waivers for one or two years past the public health emergency in the omnibus spending package expected March 11, and several sources told Inside TeleHealth they have heard the unofficial CBO scores are in the low single-figure billions, which they view as surprisingly high. Not having official CBO scores makes it more challenging for stakeholders to lobby...
Article Type: 
Site Name: 
InsideHealthPolicy.com
Author: 

Stakeholders Clash On Role Of Decision-Making A.I. In Health Care

CMS’ efforts to understand the role of artificial intelligence in health care has led stakeholders to clash over the future of these programs in patient assessment. The Center for Medicare Advocacy warns CMS that AI tools could lead providers to make decisions that go against Medicare coverage guidelines, but the Connected Health Initiative argues that AI is a powerful tool the agency could use to increase equity in health care. In health care, AI can be used to determine whether...
Article Type: 
Site Name: 
InsideHealthPolicy.com
Author: 

Provider Touts Reward-Based Apps To Treat Substance Use Disorder

A practitioner touted the benefits of using a contingency management-based app to help treat patients with substance abuse disorder and called for more providers to consider app-based treatments that are approved by FDA, speaking at a DTX West conference on digital therapeutics. Audrey Kern, global medical director of Pear Therapeutics, discussed real-world examples of app-based treatment with digital therapeutics prescriber Adam Rubenstein, a private practitioner in Chicago. Rubenstein described himself as a “patient-focused” practitioner who serves as a primary care...
Article Type: 
Site Name: 
InsideHealthPolicy.com
Author: 












Pages

Log in to access this content.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.